Rigel Pharmaceuticals (RIGL) CMO receives 24,400-share RSU equity award with 4-year vesting

Rhea-AI Filing Summary

HANNAH ALISON L. reported acquisition or exercise transactions in this Form 4 filing.

RIGEL PHARMACEUTICALS INC reported that EVP and Chief Medical Officer Alison L. Hannah received a grant of 24,400 shares of common stock in the form of Restricted Stock Units. These RSUs vest annually over four years from July 8, 2026, with the first vesting on July 8, 2027. Following adjustments, including the cancellation of 5,750 RSUs for no consideration, she holds 35,025 shares of common stock directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider HANNAH ALISON L.

Role EVP, Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	24,400	$0.00	--

Holdings After Transaction: Common Stock — 35,025 shares (Direct, null)

Footnotes (1)

1. The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from July 8, 2026, with the first annual vest occurring on July 8, 2027. Amount has been adjusted to reflect the cancellation of 5,750 restricted stock units for no consideration, which is exempt from Section 16 pursuant to Rule 16b-6(d) and Rule 16a-4(d) promulgated under the Securities Exchange Act of 1934, as amended.

Key Figures

RSU grant size: 24,400 shares Shares held after transaction: 35,025 shares Cancelled RSUs: 5,750 units +2 more

5 metrics

RSU grant size 24,400 shares Restricted Stock Unit award of common stock to EVP, Chief Medical Officer

Shares held after transaction 35,025 shares Direct common stock ownership following the reported award and adjustments

Cancelled RSUs 5,750 units Restricted Stock Units cancelled for no consideration, exempt from Section 16 rules

Vesting period 4 years RSUs vest annually over four years from July 8, 2026

First vesting date July 8, 2027 Date of first annual vesting of the RSU award

Key Terms

Restricted Stock Unit, Section 16, Rule 16b-6(d), Rule 16a-4(d)

4 terms

Restricted Stock Unit financial

"The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Section 16 regulatory

"which is exempt from Section 16 pursuant to Rule 16b-6(d) and Rule 16a-4(d)"

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

Rule 16b-6(d) regulatory

"exempt from Section 16 pursuant to Rule 16b-6(d) and Rule 16a-4(d)"

Rule 16a-4(d) regulatory

"exempt from Section 16 pursuant to Rule 16b-6(d) and Rule 16a-4(d)"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/10/2026 - 09:56 PM Accepted by SEC EDGAR 07/10/2026 - 09:53 PM Learn about SEC filing dates

FAQ

What insider transaction did RIGL disclose for EVP CMO Alison L. Hannah?

RIGEL PHARMACEUTICALS INC disclosed that EVP and Chief Medical Officer Alison L. Hannah received a grant of 24,400 Restricted Stock Units, representing common stock awarded as equity compensation.

How many shares did Alison L. Hannah acquire in the latest RIGL Form 4?

Alison L. Hannah was granted 24,400 shares of RIGEL PHARMACEUTICALS INC common stock in the form of Restricted Stock Units, with no cash price per share stated for the award.

What is the vesting schedule for Alison L. Hannah’s new RIGL RSU award?

The 24,400 Restricted Stock Units granted to Alison L. Hannah vest annually over four years from July 8, 2026, with the first vesting tranche scheduled on July 8, 2027.

How many RIGL shares does Alison L. Hannah hold after this Form 4 transaction?

After the reported equity award and related adjustments, Alison L. Hannah holds 35,025 shares of RIGEL PHARMACEUTICALS INC common stock as a direct ownership position.

What cancellation of RSUs was reported in the RIGL Form 4 for Alison L. Hannah?

The filing notes that 5,750 Restricted Stock Units were cancelled for no consideration, with the adjustment stated as exempt from Section 16 under Rules 16b-6(d) and 16a-4(d).

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HANNAH ALISON L.

(Last) (First) (Middle)

RIGEL PHARMACEUTICALS, INC.

611 GATEWAY BLVD, SUITE 900

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RIGEL PHARMACEUTICALS INC [ RIGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/08/2026		A		24,400(1)	A	$0	35,025(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares of common stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest annually over four (4) years from July 8, 2026, with the first annual vest occurring on July 8, 2027.

2. Amount has been adjusted to reflect the cancellation of 5,750 restricted stock units for no consideration, which is exempt from Section 16 pursuant to Rule 16b-6(d) and Rule 16a-4(d) promulgated under the Securities Exchange Act of 1934, as amended.

	/s/ Raymond Furey (Attorney-in-Fact)	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)